The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis
Abstract
OBJECTIVE: To evaluate the safety and efficacy of long-term treatment of psoriasis with etanercept, 50 mg twice weekly. DESIGN, SETTING, AND PATIENTS: A phase 3, randomized, double-blind trial with an open-label extension. A total of 618 adult patients with moderate to severe plaque psoriasis were studied at 39 medical centers in the United States and Canada from May 23, 2003, through June 22, 2005. INTERVENTIONS: Patients were randomized to receive placebo or etanercept for 12 weeks. Beginning with week 13, all patients (N=591) received etanercept. MAIN OUTCOME MEASURES: Exposure-adjusted adverse event rates were calculated. Efficacy measures included efficacy and patient global assessment of psoriasis. RESULTS: Exposure-adjusted rates of adverse events, serious adverse events, infections, and serious infections were similar for placebo and etanercept treatments. Nonneutralizing antibodies to etanercept, observed in 18.3% of patients, had no apparent effect on safety or efficacy. Patients responded within 2 weeks to etanercept, with statistically significant differences in the Psoriasis Area and Severity Index and Dermatology Life Quality Index between the etanercept and placebo groups at week 12. At week 24, after 12 weeks of open-label etanercept treatment, patients in the original placebo group had clinical benefits comparable to those of patients in the original etanercept group. As both groups progressed through the open-label period, the Psoriasis Area and Severity Index response peaked at week 48. At week 96, 51.6% of the original placebo-treated patients and 51.1% of the original etanercept-treated patients had improvements from baseline in the Psoriasis Area and Severity Index of at least 75%. CONCLUSIONS: Extended exposure to 50 mg of etanercept twice weekly resulted in exposure-adjusted rates of adverse events and infections similar to those in patients receiving placebo. Improvements in physician- and patient-reported measures of psoriasis severity were observed for up to 96 weeks of continuous etanercept therapy. Trial Registration clinicaltrials.gov Identifier NCT00111449.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
Etanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Self-citationTyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069 · cited 4×
“Results of the 12-week, double-blind portion of the study were reported previously.(7) This article provides results of the subsequent 84-week open-label period.”
BackgroundMethodInfluentialSelf-citationEtanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression
Mease, P. J., Kivitz, A. J., Burch, F. X., Siegel, E. L., Cohen, S. B., Ory, P., Salonen, D., Rubenstein, J., Sharp, J. T., & Tsuji, W. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20335 · Cited by 882
Papp, K. A., Tyring, S., Lahfa, M., Prinz, J., Griffiths, C. E. M., Nakanishi, A. M., Zitnik, R., van de Kerkhof, P. C. M., & the Etanercept Psoriasis Study Group (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06688.x · Cited by 693
Self-citationA Randomized Trial of Etanercept as Monotherapy for Psoriasis
Gottlieb, A. B. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.12.1627 · Cited by 470
Self-citationTrends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996
Harris, R. B., Griffith, K., & Moon, T. E. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.114742 · Cited by 228
Cited by
TNF-mediated inflammatory disease
Bradley, Jr. (2008) · The Journal of Pathology · doi:10.1002/path.2287 · Cited by 2,094
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
Hawkes, J. E., Yan, B. Y., Chan, T. C., & Krueger, J. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800013 · Cited by 593
Nast, A., Smith, C., Spuls, P. I., Avila Valle, G., Bata‐Csörgö, Z., Boonen, H., De Jong, E., Garcia‐Doval, I., Gisondi, P., Kaur‐Knudsen, D., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16915 · Cited by 420
Papp, K., Cather, J. C., Rosoph, L., Sofen, H., Langley, R. G., Matheson, R. T., Hu, C., & Day, R. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60642-4 · Cited by 282
Self-citationEffectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial
Armstrong, A. W., Chambers, C. J., Maverakis, E., Cheng, M. Y., Dunnick, C. A., Chren, M.-M., Gelfand, J. M., Wong, D. J., Gibbons, B. M., Gibbons, C. M., et al. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.3062 · Cited by 103
Metadata
- Authors
- Tyring, S., Gordon, K. B., Poulin, Y., Langley, R. G., Gottlieb, A. B., Dunn, M., & Jahreis, A.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2007-06-01
- Volume
- 143
- Issue
- 6
- Pages
- 719-26
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W2060546762
- Cited by
- 324
- References
- 16
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis. https://app.cochat.ai/papers/10.1001/archderm.143.6.719
- The paper
- Tyring, S., Gordon, K. B., Poulin, Y., Langley, R. G., Gottlieb, A. B., Dunn, M., & Jahreis, A. (2007). Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis. Archives of Dermatology. https://doi.org/10.1001/archderm.143.6.719
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
